AstraZeneca, Merck Say Lynparza Trial Achieves Primary, Secondary Endpoints
September 30 2019 - 12:19PM
Dow Jones News
By Stephen Nakrosis
AstraZeneca PLC (AZN) and Merck & Co. Inc. (MRK) on Monday
said trial results for Lynparza showed "a statistically significant
and clinically meaningful" improvement in radiographic
progression-free survival for certain patients with prostate
cancer.
Lynparza, or olaparib, also reduced the risk of the disease's
progression on death in 51% of patients who had a homologous
recombination repair gene mutation, the companies said.
The Phase III PROfound trial involved 387 men with metastatic
castration-resistant prostate cancer who also had a mutation in
their homologous recombination repair, or HRR, gene, the companies
said.
Results showed the test met the primary endpoint of radiographic
progression-free survival, "reducing the risk of disease
progression or death by a median of 7.4 months versus 3.6 months
for those receiving abiraterone or enzalutamide," the companies
said.
The trial also met the key secondary endpoint of radiographic
progression-free survival in those with HRR mutations, with
Lynparza reducing the risk of disease progression or death by 51%.
It also improved radiographic progression-free survival to a median
of 5.8 months against the 3.5 months for those receiving
abiraterone or enzalutamide, the companies said.
Results were presented at the European Society of Medical
Oncology congress in Barcelona.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 30, 2019 12:04 ET (16:04 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024